Incannex Healthcare (IXHL) Total Non-Current Liabilities (2020 - 2026)
Incannex Healthcare (IXHL) posted quarterly Total Non-Current Liabilities of $2.0 million for Q1 2026, down 73.65% year-on-year from $7.5 million in Q1 2025, and down 73.65% on a QoQ basis from $7.5 million in Q1 2025.
Incannex Healthcare (IXHL) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Incannex Healthcare (IXHL) has reported Total Non-Current Liabilities for 6 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 73.65% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 73.65% YoY) and the FY2023 annual result came in at $616087.0, changed N/A from the prior year.
- Total Non-Current Liabilities retreated to $2.0 million in Q1 2026 per IXHL's latest filing, from $7.5 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for IXHL reached as high as $8.9 million in Q4 2024 and fell as low as $181519.0 in Q4 2022.
- A 5-year average of $3.8 million and a median of $2.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 1821.01% — and 2026, when it plunged 73.65%.
- Year by year, Total Non-Current Liabilities stood at $181519.0 in 2022, then jumped by 1821.01% to $3.5 million in 2023, then soared by 153.94% to $8.9 million in 2024, then retreated by 15.62% to $7.5 million in 2025, then tumbled by 73.65% to $2.0 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $2.0 million, $7.5 million, and $8.9 million for Q1 2026, Q1 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Incannex Healthcare | 3.63 Mn | 3.63 Mn | - | 1.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.97 Mn |
| Mar 31, 2025 | 7.47 Mn |
| Dec 31, 2024 | 8.86 Mn |
| Dec 31, 2023 | 3.49 Mn |
| Jun 30, 2023 | 616,087.00 |
| Dec 31, 2022 | 181,519.00 |
| Jun 30, 2020 | 955,006.00 |